PAHC
Price
$21.90
Change
-$0.07 (-0.32%)
Updated
Apr 2 closing price
Capitalization
523.71M
34 days until earnings call
SCYX
Price
$0.95
Change
+$0.01 (+1.06%)
Updated
Apr 2 closing price
Capitalization
55.88M
35 days until earnings call
Ad is loading...

PAHC vs SCYX

Header iconPAHC vs SCYX Comparison
Open Charts PAHC vs SCYXBanner chart's image
Phibro Animal Health
Price$21.90
Change-$0.07 (-0.32%)
Volume$142.34K
Capitalization523.71M
SCYNEXIS
Price$0.95
Change+$0.01 (+1.06%)
Volume$30.95K
Capitalization55.88M
PAHC vs SCYX Comparison Chart
Loading...
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PAHC vs. SCYX commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PAHC is a Hold and SCYX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (PAHC: $21.90 vs. SCYX: $0.95)
Brand notoriety: PAHC and SCYX are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: PAHC: 48% vs. SCYX: 22%
Market capitalization -- PAHC: $523.71M vs. SCYX: $55.88M
PAHC [@Pharmaceuticals: Other] is valued at $523.71M. SCYX’s [@Pharmaceuticals: Other] market capitalization is $55.88M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PAHC’s FA Score shows that 2 FA rating(s) are green whileSCYX’s FA Score has 0 green FA rating(s).

  • PAHC’s FA Score: 2 green, 3 red.
  • SCYX’s FA Score: 0 green, 5 red.
According to our system of comparison, PAHC is a better buy in the long-term than SCYX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PAHC’s TA Score shows that 4 TA indicator(s) are bullish while SCYX’s TA Score has 3 bullish TA indicator(s).

  • PAHC’s TA Score: 4 bullish, 5 bearish.
  • SCYX’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, PAHC is a better buy in the short-term than SCYX.

Price Growth

PAHC (@Pharmaceuticals: Other) experienced а +1.20% price change this week, while SCYX (@Pharmaceuticals: Other) price change was -4.42% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.35%. For the same industry, the average monthly price growth was +65.59%, and the average quarterly price growth was -10.19%.

Reported Earning Dates

PAHC is expected to report earnings on May 07, 2025.

SCYX is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-2.35% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PAHC($524M) has a higher market cap than SCYX($55.9M). PAHC has higher P/E ratio than SCYX: PAHC (34.11) vs SCYX (1.06). PAHC YTD gains are higher at: 4.808 vs. SCYX (-21.488). PAHC has higher annual earnings (EBITDA): 83.7M vs. SCYX (70.9M). PAHC has more cash in the bank: 92.5M vs. SCYX (74.4M). SCYX has less debt than PAHC: SCYX (15.1M) vs PAHC (513M). PAHC has higher revenues than SCYX: PAHC (982M) vs SCYX (140M).
PAHCSCYXPAHC / SCYX
Capitalization524M55.9M937%
EBITDA83.7M70.9M118%
Gain YTD4.808-21.488-22%
P/E Ratio34.111.063,203%
Revenue982M140M701%
Total Cash92.5M74.4M124%
Total Debt513M15.1M3,397%
FUNDAMENTALS RATINGS
PAHC vs SCYX: Fundamental Ratings
PAHC
SCYX
OUTLOOK RATING
1..100
610
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
55
Fair valued
PROFIT vs RISK RATING
1..100
95100
SMR RATING
1..100
7897
PRICE GROWTH RATING
1..100
4384
P/E GROWTH RATING
1..100
2098
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAHC's Valuation (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for SCYX (55) in the Pharmaceuticals Other industry. This means that PAHC’s stock grew somewhat faster than SCYX’s over the last 12 months.

PAHC's Profit vs Risk Rating (95) in the Pharmaceuticals Major industry is in the same range as SCYX (100) in the Pharmaceuticals Other industry. This means that PAHC’s stock grew similarly to SCYX’s over the last 12 months.

PAHC's SMR Rating (78) in the Pharmaceuticals Major industry is in the same range as SCYX (97) in the Pharmaceuticals Other industry. This means that PAHC’s stock grew similarly to SCYX’s over the last 12 months.

PAHC's Price Growth Rating (43) in the Pharmaceuticals Major industry is somewhat better than the same rating for SCYX (84) in the Pharmaceuticals Other industry. This means that PAHC’s stock grew somewhat faster than SCYX’s over the last 12 months.

PAHC's P/E Growth Rating (20) in the Pharmaceuticals Major industry is significantly better than the same rating for SCYX (98) in the Pharmaceuticals Other industry. This means that PAHC’s stock grew significantly faster than SCYX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PAHCSCYX
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
69%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
70%
Bullish Trend 18 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
71%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WFICX13.61N/A
N/A
North Star Small Cap Value Institutional
PJRCX7.55N/A
N/A
PGIM Quant Solutions International Eq C
ACAAX29.97N/A
N/A
Alger Capital Appreciation A
STESX13.64N/A
N/A
Bernstein International Strat Eqs SCB
GCEUX83.96N/A
N/A
Green Century Equity Institutional

PAHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with PBH. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then PBH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAHC
1D Price
Change %
PAHC100%
-0.32%
PBH - PAHC
35%
Loosely correlated
+0.35%
EVO - PAHC
25%
Poorly correlated
-3.29%
IRWD - PAHC
24%
Poorly correlated
+2.13%
SCYX - PAHC
24%
Poorly correlated
+0.81%
LFCR - PAHC
23%
Poorly correlated
+2.42%
More

SCYX and

Correlation & Price change

A.I.dvisor tells us that SCYX and CRON have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCYX and CRON's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCYX
1D Price
Change %
SCYX100%
+0.81%
CRON - SCYX
29%
Poorly correlated
+1.12%
ITCI - SCYX
29%
Poorly correlated
N/A
TXMD - SCYX
29%
Poorly correlated
+2.04%
ACET - SCYX
27%
Poorly correlated
-1.50%
OGI - SCYX
27%
Poorly correlated
-0.96%
More